Current tobacco smoking and risk of SARS-CoV-2 infection and hospitalization: Evaluating the role of socio-demographic factors and comorbidities

被引:2
|
作者
Young-Wolff, Kelly C. [1 ,2 ,5 ]
Slama, Natalie [1 ]
Sakoda, Lori C. [1 ]
Prochaska, Judith J. [3 ]
Fogelberg, Renee [4 ]
Alexeeff, Stacey E. [1 ]
机构
[1] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA
[2] Univ Calif San Francisco, Dept Psychiat & Behav Sci, San Francisco, CA USA
[3] Stanford Univ, Stanford Prevent Res Ctr, Stanford, CA USA
[4] Kaiser Permanente Northern Calif, Richmond Med Ctr, Richmond, CA USA
[5] Kaiser Permanente Northern Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA
关键词
COVID-19; SARS-CoV-2; Smoking; Tobacco; Nicotine; Comorbidities; Age; Race; Hospitalization;
D O I
10.1016/j.ypmed.2023.107523
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Our recently published study of >2.4 million adults in Northern California indicated that current versus never-tobacco smoking was associated with lower risk of SARS-CoV-2 infection and less severe coronavirus disease 2019 (COVID-19). We extended this research by evaluating whether these associations were moderated by socio-demographic factors and medical comorbidities. This retrospective cohort study of 1,885,826 adults with current or never-smoking status in Kaiser Permanente Northern California from 3/5/2020 (baseline) to 12/31/2020 (pre-vaccine) included electronic health record-based socio-demographics (sex, age, race/ethnicity, neighbor-hood deprivation index (NDI)) and medical comorbidities (obesity, cardiovascular conditions, diabetes, renal disease, respiratory conditions). We estimated the adjusted risk of SARS-CoV-2 infection and hospitalization (<= 30 days of infection) associated with smoking status using Cox proportional hazard regression models. We estimated associations within subgroups of socio-demographics and comorbidities, and tested for effect modi-fication using interaction terms. During the study, 35,627 patients had SARS-CoV-2 infection. Current versus never-smoking status was associated with lower adjusted rates of SARS-CoV-2 infection (aHR ranging from 0.51 to 0.89) and hospitalization (aHR ranging from 0.32 to 0.70) within nearly every socio-demographic and co-morbidity subgroup. Statistically significant interactions showed that the magnitude of protection for SARS-CoV-2 infection varied by sex, age, race/ethnicity, NDI, cardiovascular conditions and diabetes, and for SARS-CoV-2 hospitalization by age and renal disease. Taken together, results indicated that while some socio-demographics and comorbidities moderated the associations, the lower risk of SARS-CoV-2 infection and hospitalization associated with current versus never-smoking status persisted among patients regardless of socio-demographics or comorbidities.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Risk factors for hospitalization for cancer patients with SARS-CoV-2 infection.
    Shahid, Zainab
    Baldrige, Emily
    Trufan, Sally
    Schepel, Courtney
    Tan, Antoinette R.
    Hwang, Jimmy J.
    Musselwhite, Laura W.
    Kim, Edward S.
    Chai, Seungjean
    Sumrall, Ashley Love
    Ragon, Brittany K.
    Voorhees, Peter Michael
    Grunwald, Michael Richard
    Ghosh, Nilanjan
    Usmani, Saad Zafar
    Copelan, Edward Alan
    Raghavan, Derek
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection
    Eik Schäfer
    Christian Scheer
    Karen Saljé
    Anja Fritz
    Thomas Kohlmann
    Nils-Olaf Hübner
    Matthias Napp
    Lizon Fiedler-Lacombe
    Dana Stahl
    Bernhard Rauch
    Matthias Nauck
    Uwe Völker
    Stephan Felix
    Guglielmo Lucchese
    Agnes Flöel
    Stefan Engeli
    Wolfgang Hoffmann
    Klaus Hahnenkamp
    Mladen V. Tzvetkov
    [J]. Scientific Reports, 12
  • [3] Factors associated with the risk of hospitalization and death related to SARS-CoV-2 infection
    de Diego-Castell, Maria del Carmen
    Garcia-Lopez, Eduardo
    Gonzalez-Gonzalez, Jaime
    Alvarez-Gregori, Joaquin Antonio
    Mohedano-Moriano, Alicia
    Criado-Alvarez, Juan Jose
    [J]. REVISTA ESPANOLA DE SALUD PUBLICA, 2023, 97
  • [4] Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection
    Schaefer, Eik
    Scheer, Christian
    Salje, Karen
    Fritz, Anja
    Kohlmann, Thomas
    Huebner, Nils-Olaf
    Napp, Matthias
    Fiedler-Lacombe, Lizon
    Stahl, Dana
    Rauch, Bernhard
    Nauck, Matthias
    Voelker, Uwe
    Felix, Stephan
    Lucchese, Guglielmo
    Floeel, Agnes
    Engeli, Stefan
    Hoffmann, Wolfgang
    Hahnenkamp, Klaus
    Tzvetkov, Mladen, V
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [5] Prevalence and socio-demographic factors of SARS-CoV-2 antibody in multi-ethnic healthcare workers
    Patel, Mehool
    Nair, Meera
    Pirozzoli, Eric
    Cienfuegos, Marta C.
    Aitken, Elizabeth
    [J]. CLINICAL MEDICINE, 2021, 21 (01) : E5 - E8
  • [6] Socio-Demographic Factors Involved in a Low-Incidence Phase of SARS-CoV-2 Spread in Sicily, Italy
    Amodio, Emanuele
    Battisti, Michele
    Maida, Carmelo Massimo
    Zarcone, Maurizio
    Casuccio, Alessandra
    Vitale, Francesco
    [J]. HEALTHCARE, 2021, 9 (07)
  • [7] Socio-demographic Heterogeneity in Prevalence of SARS-COV-2 Infection and Death Rate: Relevance to Black College Student Knowledge of COVID-19 and SARS-COV-2
    Emrani, Jahangir
    Hefner, Elia Nichelle
    [J]. JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES, 2023, 10 (01) : 14 - 31
  • [8] Socio-demographic Heterogeneity in Prevalence of SARS-COV-2 Infection and Death Rate: Relevance to Black College Student Knowledge of COVID-19 and SARS-COV-2
    Jahangir Emrani
    Elia Nichelle Hefner
    [J]. Journal of Racial and Ethnic Health Disparities, 2023, 10 : 14 - 31
  • [9] Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking
    Engin, Ayse Basak
    Engin, Evren Doruk
    Engin, Atilla
    [J]. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2020, 78
  • [10] Symptoms, comorbidities and their medication as risk factors for hospitalization after SARS-CoV-2 infection: a prospective observational study from the Northeast of Germany
    Schaefer, E.
    Scheer, C.
    Hoffmann, W.
    Engeli, S.
    Hahnenkamp, K.
    Tzvetkov, M. V.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2022, 395 (SUPPL 1) : S23 - S23